Health Canada Sets Guardrails for Decentralized Clinical Trials

Health Canada has published guidance explaining how existing Canadian drug-trial requirements apply when some research activities take place outside a traditional clinical-trial site. The October 27 update covers “decentralized elements” such as virtual visits, home-based activities, electronic consent, remote data collection, participation by local health professionals and delivery of investigational medicines closer to participants.

The guidance does not create a separate, less regulated route for remote trials. The regulator says the same core requirements for participant protection, data integrity and regulatory compliance continue to apply. Instead, it describes how sponsors, investigators and other partners should plan and oversee trial activities when they are spread across homes, local care settings and digital systems.

What the guidance covers

The document applies to human drug trials conducted in Canada, including phases I through IV and trials involving pharmaceuticals, biologics and radiopharmaceuticals. Health Canada says it applies not only to sponsors and investigators, but also to other parties involved in conducting trials, including healthcare providers, clinical laboratories, academic teams and service vendors.

Decentralized designs can move part or all of trial participation away from the usual research centre. A participant might complete a visit by video, receive a study-related service closer to home, complete consent electronically or use technology to send study data. In some designs, a local provider may support a participant or an investigational product may be shipped nearer to them. The guidance recognizes that these options can reduce travel and logistical barriers and could broaden who is able to take part.

Access gains still depend on careful design

Remote access does not automatically make a trial accessible to everyone. Health Canada points to potential inequities in access to technology and reliable internet, alongside the need to consider participants’ language, care needs and personal circumstances. The guidance encourages study designs that are operationally feasible, participant-centred and proportionate to risk. Where possible, participants should have flexibility to opt in or out of decentralized elements as their needs change.

The regulator also notes that community-based providers may help connect patients with research or take part in broader studies. That opportunity can come with added work: training, trial-specific procedures, appropriate equipment and staffing, oversight, communication with the research team, and shipping, handling and storage of study medicines under the protocol. The update makes clear that these responsibilities need to be planned rather than assumed to be covered by routine clinical workflows.

What it could mean for pharmacy teams

For pharmacists and other local health professionals invited to support a trial, the practical starting point is to understand exactly which activities have been delegated, who remains accountable for each decision and how urgent safety issues will be escalated. A pharmacy asked to receive, store or hand off an investigational medicine should follow the study protocol and the sponsor’s instructions for product handling, documentation, temperature control and communication. A routine prescription workflow should not be treated as a substitute for trial-specific training or oversight.

Pharmacy leaders considering a research partnership may also want to clarify staffing, equipment, privacy and workload expectations before agreeing to participate. The guidance highlights multi-site drug handling, digital technologies, inspection readiness, risk-proportionate quality management, participant accessibility and the respective roles of sponsors, qualified investigators, delegated staff and service providers. Those areas are relevant to operational planning; the notice does not impose a single pharmacy workflow or say every community pharmacy should offer trial services.

What changes—and what does not

Health Canada says it strengthened and reorganized the guidance after receiving 35 submissions on its 2025 draft from stakeholders including sponsors, researchers, health professionals, ethics boards and patient groups. The current document is based on existing Part C, Division 5 requirements and the interim approach to clinical-trial modernization. It is guidance for applying current rules, not a replacement for the regulations or a finding that every remote design is acceptable.

The agency expects to publish final regulations for its modernized clinical-trial framework in the Canada Gazette, Part II, in spring 2027, followed by a one-year period before they come into force. Health Canada says it will update the guidance again to reflect that framework. Until then, sponsors and investigators remain responsible for ensuring that each trial’s design, delegation and safeguards meet the requirements that already apply.

For pharmacists, the immediate takeaway is to treat decentralized research as a protocol-led activity: clarify responsibilities, training, product logistics and escalation arrangements before accepting a delegated role.